

LA JOLLA PHARMACEUTICAL CO  
Form 8-K  
February 04, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): January 31, 2013**

**LA JOLLA PHARMACEUTICAL COMPANY**

**(Exact name of registrant as specified in its charter)**

**California**  
**(State or other jurisdiction of**  
**incorporation or organization)**

**0-24274**  
**(Commission**  
**File Number)**

**33-0361285**  
**(I.R.S. Employer**  
**Identification No.)**

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 8-K

**4370 La Jolla Village Drive, Suite 400,**

**San Diego, California**  
(Address of Principal Executive Offices)

**92122**  
(Zip Code)

**Registrant's telephone number, including area code: (858) 207-4264**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 7.01 REGULATION FD DISCLOSURE.**

On January 31, 2013, La Jolla Pharmaceutical Company (the Company) hosted a presentation at the 2013 Orlando World MoneyShow. The presentation is available on MoneyShow.com for a limited time. If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days at <http://www.moneyshow.com>. A copy of the presentation from the event is attached hereto as Exhibit 99.1 and is also posted on the Company's website at <http://www.ljpc.com/investors-main.html>.

*The information set forth under Item 7.01 and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.*

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.**

(d) *Exhibits.* The following exhibit is filed with this report on Form 8-K:

<b>Exhibit No.</b>	<b>Description</b>
99.1	Presentation used in connection with the 2013 Orlando World MoneyShow January 31, 2013.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LA JOLLA PHARMACEUTICAL COMPANY

Date: February 4, 2013

By: /s/ George Tidmarsh  
Name: George Tidmarsh, M.D., Ph.D.  
Title: President and Chief Executive Officer

-3-